COVID-19 and Autoimmune/Autoinflammatory Rheumatic Disease Patients: Lessons Learned and Questions Anticipating Answers.
作者信息
Bakasis Athanasios-Dimitrios, Moutsopoulos Haralampos M
机构信息
Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Academy of Athens, Athens, Greece.
出版信息
Mediterr J Rheumatol. 2021 Sep 6;32(3):188-191. doi: 10.31138/mjr.32.3.188. eCollection 2021 Sep.
Abstract
摘要
相似文献
1
COVID-19 and Autoimmune/Autoinflammatory Rheumatic Disease Patients: Lessons Learned and Questions Anticipating Answers.
Mediterr J Rheumatol. 2021 Sep 6;32(3):188-191. doi: 10.31138/mjr.32.3.188. eCollection 2021 Sep.
2
A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review.
Clin Rheumatol. 2021 Sep;40(9):3533-3545. doi: 10.1007/s10067-021-05700-z. Epub 2021 Mar 22.
3
Epigenetics for Clinicians from the Perspective of Pediatric Rheumatic Diseases.
Curr Rheumatol Rep. 2020 Jul 11;22(8):46. doi: 10.1007/s11926-020-00912-9.
4
Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020.
Joint Bone Spine. 2020 Oct;87(5):431-437. doi: 10.1016/j.jbspin.2020.05.006. Epub 2020 May 27.
5
Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.
Front Immunol. 2021 Mar 12;12:645013. doi: 10.3389/fimmu.2021.645013. eCollection 2021.
6
Perception of self: distinguishing autoimmunity from autoinflammation.
Nat Rev Rheumatol. 2015 Aug;11(8):483-92. doi: 10.1038/nrrheum.2015.60. Epub 2015 May 12.
7
Mutations/polymorphisms in a monogenetic autoinflammatory disease may be susceptibility markers for certain rheumatic diseases: lessons from the bedside for the benchside.
Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S29-31.
8
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases.
Curr Rheumatol Rep. 2016 Feb;18(2):8. doi: 10.1007/s11926-015-0558-4.
9
Role of vaccinations and prophylaxis in rheumatic diseases.
Best Pract Res Clin Rheumatol. 2015 Apr;29(2):306-18. doi: 10.1016/j.berh.2015.02.001. Epub 2015 Apr 2.
10
Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases.
J Eur Acad Dermatol Venereol. 2014 Jun;28(6):741-6. doi: 10.1111/jdv.12169. Epub 2013 Apr 17.
引用本文的文献
1
Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases.
Clin Rheumatol. 2023 Dec;42(12):3375-3385. doi: 10.1007/s10067-023-06769-4. Epub 2023 Sep 21.
2
Clinical Features and Outcomes of Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease and Spondyloarthropathies.
Turk J Gastroenterol. 2022 Sep;33(9):751-759. doi: 10.5152/tjg.2022.22181.
本文引用的文献
1
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet. 2021 Sep 4;398(10303):856-869. doi: 10.1016/S0140-6736(21)01694-9. Epub 2021 Aug 6.
2
COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review.
J Autoimmun. 2021 Sep;123:102687. doi: 10.1016/j.jaut.2021.102687. Epub 2021 Jul 16.
3
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Ann Rheum Dis. 2021 Oct;80(10):1330-1338. doi: 10.1136/annrheumdis-2021-220647. Epub 2021 Jun 14.
4
A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine.
J Autoimmun. 2021 Jul;121:102649. doi: 10.1016/j.jaut.2021.102649. Epub 2021 May 1.
5
High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry.
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001461.
6
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Ann Rheum Dis. 2021 Jul;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.
7
Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison.
Nat Immunol. 2021 Jan;22(1):32-40. doi: 10.1038/s41590-020-00840-x. Epub 2020 Dec 4.
8
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
9
Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients.
Ann Rheum Dis. 2021 Apr;80(4):527-538. doi: 10.1136/annrheumdis-2020-218310. Epub 2020 Dec 2.
10
Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?
Mediterr J Rheumatol. 2020 Sep 21;31(Suppl 2):259-267. doi: 10.31138/mjr.31.3.259. eCollection 2020 Sep.
Zotero 插件